Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · IEX Real-Time Price · USD
5.13
-0.11 (-2.10%)
Apr 19, 2024, 4:00 PM EDT - Market closed

Company Description

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.

It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components.

It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States.

Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Sight Sciences, Inc.
Sight Sciences logo
Country United States
Founded 2011
IPO Date Jul 15, 2021
Industry Medical Devices
Sector Healthcare
Employees 214
CEO Paul Badawi

Contact Details

Address:
4040 Campbell Ave, Suite 100
Menlo Park, California 94025
United States
Phone (415) 889-0550
Website sightsciences.com

Stock Details

Ticker Symbol SGHT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $24.00
CIK Code 0001531177
CUSIP Number 82657M105
ISIN Number US82657M1053
Employer ID 80-0625749
SIC Code 3841

Key Executives

Name Position
Paul Badawi Co-Founder, President, Chief Executive Officer and Director
Dr. David Badawi M.D. Founder, Chief Technology Officer and Director
Sam Boong Park Chief Operating Officer
Alison Perry Bauerlein Chief Financial Officer and Treasurer
Jeremy B. Hayden Chief Legal Officer
Steve R. Tamayo Jr. Vice President and Chief Ethics and Compliance Officer
Dr. Reay H. Brown Chief Medical Officer
Tom Huang Head of Corporate Strategy and Development
Matthew W. Link Chief Commercial Officer
Stephen B. Thau J.D. Secretary

Latest SEC Filings

Date Type Title
Apr 3, 2024 144 Filing
Apr 3, 2024 144 Filing
Apr 3, 2024 144 Filing
Apr 3, 2024 144 Filing
Apr 3, 2024 144 Filing
Mar 13, 2024 10-K Annual Report
Mar 7, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals